Fabry Disease on Peritoneal Dialysis with Cardiac Involvement

Intern Med. 2021 May 15;60(10):1561-1565. doi: 10.2169/internalmedicine.5992-20. Epub 2020 Dec 22.

Abstract

Fabry disease (FD) is an X-linked lysosomal storage disorder resulting from a lack of alpha-galactosidase A (AGALA) activity in lysosomes. We herein report a patient with FD revealed by a renal biopsy who survived seven years after the introduction of peritoneal dialysis despite having severe heart failure due to left ventricular hypertrophy (LVH). FD was diagnosed based on a renal biopsy and biochemical analysis showing a low enzymatic activity of AGALA. A microscopic examination at the autopsy revealed marked hypertrophy and vacuolation of cardiac muscle cells. In our case, cardiac involvement determined the prognosis. Peritoneal dialysis is the modality of choice in the long-term management of dialysis patients with FD.

Keywords: Fabry disease; Zebra body; left ventricular hypertrophy; peritoneal dialysis.

MeSH terms

  • Fabry Disease* / complications
  • Fabry Disease* / diagnosis
  • Humans
  • Hypertrophy, Left Ventricular / diagnosis
  • Hypertrophy, Left Ventricular / etiology
  • Peritoneal Dialysis* / adverse effects
  • Renal Dialysis
  • alpha-Galactosidase

Substances

  • alpha-Galactosidase